1. Home
  2. MVST vs INBX Comparison

MVST vs INBX Comparison

Compare MVST & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microvast Holdings Inc.

MVST

Microvast Holdings Inc.

HOLD

Current Price

$1.42

Market Cap

987.8M

Sector

Miscellaneous

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$106.61

Market Cap

999.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVST
INBX
Founded
2006
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
987.8M
999.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
MVST
INBX
Price
$1.42
$106.61
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$6.00
$150.00
AVG Volume (30 Days)
3.1M
509.2K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,300,000.00
Revenue This Year
$24.55
N/A
Revenue Next Year
$17.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
550.00
52 Week Low
$1.37
$12.80
52 Week High
$7.12
$155.29

Technical Indicators

Market Signals
Indicator
MVST
INBX
Relative Strength Index (RSI) 36.51 48.58
Support Level N/A $69.30
Resistance Level $2.49 $155.29
Average True Range (ATR) 0.14 13.09
MACD -0.02 -2.08
Stochastic Oscillator 16.66 14.74

Price Performance

Historical Comparison
MVST
INBX

About MVST Microvast Holdings Inc.

Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: